Drug Pipeline
New drugs likely to offer patients more options. Key consideration for payors will be effectively balancing high — and rising — price tags with appropriate access. More
Feature
“Drug Pipeline”
14 result(s)
Drug Pipeline
CVS Health provides an early look at some key Breakthrough Therapies expected to be reviewed by the FDA in 2020 as well as the associated cost implications and expected approval... More
Feature
Drug Pipeline
New drugs to treat migraine are approaching approval and could bring relief for many patients, but they portend higher costs. Ongoing monitoring and appropriate utilization... More
Feature
Drug Pipeline
Biosimilars are a critical tool PBMs can use to help increase market competition and lower costs – we made changes to our template formularies for categories that now have... More
Feature
Drug Pipeline
An overview of recently approved therapies, anticipated approvals in the year to come, and strategies to help manage the pipeline More
Feature
Drug Pipeline
Peanut allergy is the most common of childhood food allergies — and getting more common. Research presented at the annual meeting of the American College of Allergy, Asthma and... More
Feature
Specialty
CVS Health’s three-tier specialty formulary design separates the increasingly more expensive specialty therapies into three distinct copay or coinsurance categories. Paired with... More
Briefing
Drug Pipeline
Scientific developments are altering the pace and focus of specialty drug development, while regulatory changes are shortening approval times. This poses new challenges for payors... More
Briefing
Specialty
While the launch time is uncertain, potential PAH generics could give payors greater cost control opportunities for a complex, expensive condition requiring lifelong treatment. More
Briefing
Specialty
Gene therapies bring hope for patients with conditions with few or no treatments, but also other considerations including safety and cost. More
Feature